Migraine during pregnancy: Options for therapy

CNS Drugs

Volumn 19, Issue 6, 2005, Pages 465-481

  Fox, Anthony W ^a   Diamond, Merle L ^b   Spierings, Egilius L H ^c  

^a EBD Group   (United States)

^b DIAMOND HEADACHE CLINIC   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOPHENAZONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUTALBITAL; CAFFEINE; CODEINE; DIHYDROERGOTAMINE; ERGOT ALKALOID; ERGOTAMINE; FLUNARIZINE; HERBACEOUS AGENT; HYDROMORPHONE; IBUPROFEN; ISOMETHEPTENE; METHYSERGIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PARACETAMOL; PIZOTIFEN; SEDATIVE AGENT; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SUMATRIPTAN; UNINDEXED DRUG;

ABORTION; ANAMNESIS; ASTHMA; BEHAVIOR DISORDER; BIRTH DEFECT; BRADYCARDIA; CLINICAL TRIAL; COMORBIDITY; CRANIOFACIAL MALFORMATION; DEPRESSION; DEVELOPMENTAL DISORDER; DIAGNOSTIC ACCURACY; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DUCTUS ARTERIOSUS OBLITERATION; ENDOCARDIUM; EPILEPSY; FEEDING DISORDER; FETAL ALCOHOL SYNDROME; FETUS DISTRESS; FETUS HEART RATE; FIBROSIS; FIRST TRIMESTER PREGNANCY; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HOMEOPATHY; HUMAN; LOW BIRTH WEIGHT; LUNG FIBROSIS; MIGRAINE; MOEBIUS SYNDROME; NAUSEA AND VOMITING; NEURAL TUBE DEFECT; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY POLYCYSTIC DISEASE; PREGNANCY; PREMATURE LABOR; PRESCRIPTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROPERITONEAL FIBROSIS; REVIEW; REYE SYNDROME; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; SEIZURE; TERATOGENICITY; THIRD TRIMESTER PREGNANCY; TRANSFORMED MIGRAINE;

ANALGESICS; ANIMALS; FEMALE; HUMANS; MIGRAINE DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 23044516185     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200519060-00001     Document Type: Review

References (135)

1. Stewart WF, Linet MS, Celentano DD, et al. Age- and sex-specific rates of migraine with and without visual aura. Am J Epidemiol 1991; 134: 1111-20
2. Scher AI, Stewart WF, Lipton RB. Migraine and headache: a meta-analytic approach. In: Crombie I, editor. Epidemiology of pain. Seattle (WA): IASP, 1999: 159-70
3. Stang P, Osterhaus J. Impact of migraine in the United States: data from the National Health Interview Survey. Headache 1993; 33: 29-35
4. Silberstein SD. Hormone-related headache. Med Clin North Am 2001; 85: 1017-35
5. Fox AW, Davis RL. Migraine chronobiology. Headache 1998; 38: 436-41
6. Marcus DA, Scharff L, Turk D. Longitudinal prospective study of headache during pregnancy and postpartum. Headache 1999; 39: 625-32
7. Sances G, Granella F, Nappi RE, et al. Course of migraine during pregnancy and postpartum. Cephalalgia 2003; 23: 197-205
8. Chen TC, Leviton A. Headache recurrence in pregnant women with migraine. Headache 1994; 34: 107-10
9. Granella F, Sances G, Pucci E, et al. Migraine with aura and reproductive life events: a case control study. Cephalalgia 2000; 20: 701-7
10. Olesen J, Bousser M-G, Diener HC, et al. The international classification of headache disorders. 2nd ed. Cephalalgia 2004; 24 Suppl. 1: 1-160
11. Spierings ELH, Ranke AH, Honkoop PC. Precipitating and aggravating factors of migraine versus tension-type headache. Headache 2001; 41: 554-8
12. Diamond ML. Emergency room treatment of migraine head-ache. Curr Treat Options Neurol 2002; 4: 351-6
13. Diamond ML. Emergency department management of the acute headache. Clin Cornerstone 1999; 1: 45-54
14. Silberstein SD. Migraine and pregnancy. Neurol Clin 1997; 15: 209-31
15. Spierings ELH. Acute and chronic hypertensive headache and hypertensive encephalopathy. Cephalalgia 2002; 22: 313-6
16. Modi M, Modi G. Case reports: postpartum cerebral angiopathy in a patient with chronic migraine with aura. Headache 2000; 40: 677-81
17. Bending JJ. Recurrent bilateral reversible migrainous hemiparesis during pregnancy. CMAJ 1982; 127: 508-9
18. Jacobson SL, Redman CW. Basilar migraine with loss of consciousness in pregnancy. Case report. Br J Obstet Gynaecol 1989; 96: 494-5
19. Mandel S. Hemiplegic migraine in pregnancy. Headache 1988; 28: 414-6
20. Barbour PJ, Castaldo JE, Shoemaker EI. Hemiplegic migraine during pregnancy: unusual magnetic resonance appearance with SPECT scan correlation. Headache 2001; 41: 310-6
21. Marcoux S, Berube S, Brisson J, et al. History of migraine and risk of pregnancy-induced hypertension. Epidemiology 1992; 3: 53-6
22. Evans RW, Rothrock JF. Migraine aura without headache versus transient ischemic attack during pregnancy. Headache 2001; 41: 414-5
23. Passchier J, Kaminsky MM, Paarlberg KM, et al. Stress during pregnancy is unrelated to headache change in migraineurs [letter]. Headache 1996; 36: 189
24. Chancellor AM, Wroe SJ, Cull RE. Migraine occurring for the first time during pregnancy. Headache 1990; 30: 224-7
25. Uknis A, Silberstein SD. Review article: migraine and pregnancy. Headache 1991; 31: 372-4
26. Maggioni F, Alessi C, Maggino T, et al. Headache during pregnancy. Cephalalgia 1997; 17: 765-9
27. Tfelt-Hansen P. Drug treatment of migraine: acute treatment and migraine prophylaxis. Curr Opin Neurol 1996; 9: 211-3
28. Coppola M, Yealy DM, Leibold RA. Randomized, placebocontrolled evaluation of prochlorperazine versus metoclo-pramide for emergency department treatment of migraine headache. Ann Emerg Med 1995; 26: 541-6
29. Cameron JD, Lane PL, Speechley M. Intravenous chlorpromazine versus intravenous metoclopramide in acute migraine headache. Acad Emerg Med 1995; 2: 597-602
30. Sinha C, Ohadike P, Carrick P, et al. Neonatal outcome following maternal opiate use in late pregnancy. Int J Gynaecol Obstet 2001; 74: 241-46
31. Sharpe C, Kuschel C. Outcomes of infants born to mothers receiving methadone for pain management in pregnancy. Arch Dis Child Fetal Neonatal Ed 2004; 89: F33-6
32. McCarthy JE, Siney C, Shaw NJ, et al. Outcome predictors in pregnant opiate and polydrug users. Eur J Pediatr 1999; 158: 748-49
33. Malanga CJ, Kosofsky BE. Mechanisms of action of drugs of abuse on the developing fetal brain. Clin Perinatol 1999; 26: 17-37
34. Flint C, Larsen H, Nielsen GL, et al. Pregnancy outcome after suicide attempt by drug use: a Danish population-based study. Acta Obstet Gynecol Scand 2002; 81: 516-22
35. Vainio M, Kujansuu E, Iso-Mustajarvi M, et al. Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. Br J Obstet Gynaecol 2002; 109: 161-7
36. Remez L. Daily dose of aspirin in pregnancy appears to be ineffective in preventing or treating pre-eclampsia. Fam Plann Perspect 1994; 26: 239-40
37. Regan L, Rai R. Thrombophilia and pregnancy loss. J Reprod Immunol 2002; 55: 163-80
38. Rote NS. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials [letter]. Obstet Gynecol 2002; 100: 173
39. Carmona F, Font J, Azulay M, et al. Risk factors associated with fetal losses in treated anti-phospholipid syndrome pregnancies: a multivariate analysis. Am J Reprod Immunol 2001; 46: 274-9
40. Lee RM, Silver RM. Recurrent pregnancy loss: summary and clinical recommendations. Semin Reprod Med 2000; 18: 433-40
41. Nomura T, Isa Y, Kurokawa N, et al. Enhancement effects of barbital on the teratogenicity of aminopyrine. Toxicology 1984; 29: 281-91
42. Alano MA, Ngougmna E, Ostrea EM, et al. Analysis of nonsteroidal anti-inflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics 2001; 107: 519-23
43. Morris JL, Rosen DA, Rosen KR. Nonsteroidal anti-inflammatory agents in neonates. Pediatr Drugs 2003; 5: 385-05
44. Silberstein SD, Saper J, Freitag FG. Migraine diagnosis and treatment. In: Silberstein SD, Lipton RB, Dalessio DJ, editors. Wolff's headache and other head pain. 7th ed. Oxford: Oxford University Press, 2001: 157
45. Raja M, Altavista MC, Azzoni A, et al. Severe barbiturate withdrawal syndrome in a migrainous patient. Headache 1996; 36: 119-21
46. Blumenthal I, Lindsay S. Neonatal barbiturate withdrawal. Postgrad Med J 1977; 53: 157-8
47. Ostrea EM. Neonatal withdrawal from intrauterine exposure to butalbital. Am J Obstet Gynecol 1982; 143: 597-8
48. Dessens AB, Cohen-Kettenis PT, Mellenbergh GJ, et al. Association of prenatal phenobarbital and phenytoin exposure with genital anomalies and menstrual disorders. Teratology 2001; 64: 181-88
49. Holmes LB, Wyszynski DF, Liberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 2004; 61: 673-78
50. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344: 1132-38
51. Ching M. Effect of barbital on the pituitary-thyroid axis. J Endocrinol Invest 1981; 4: 389-92
52. McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol 1994; 8: 461-75
53. Erkkola R, Kero P, Kanto J, et al. Severe abuse of psychotropic drugs during pregnancy with good perinatal outcome. Ann Clin Res 1983; 15: 88-91
54. Mazzotta P, Magee LA. A risk-benefit assessment of pharmacological and non-pharmacological treatments for nausea and vomiting of pregnancy. Drugs 2000; 59: 781-800
55. Nehlig A, Debry G. Potential teratogenic and neurodevelopmental consequences of coffee and caffeine exposure: a review of human and animal data. Neurotoxicol Teratol 1994; 16: 531-43
56. Bracken MB, Triche EW, Belanger K, et al. Association of maternal caffeine consumption with decrements in fetal growth. Am J Epidemiol 2003; 157: 456-66
57. Diekman MA, Green ML. Mycotoxins and reproduction in domestic livestock. J Anim Sci 1992; 70: 1615-27
58. Baskett TF. A flux of the reds: evolution of active management of the third stage of labour. J R Soc Med 2000; 93: 489-93
59. Fox AW. Migraine therapy: seamlessness between plant-derived and synthetic drugs. J Herb Pharmacother 2002; 2: 3-18
60. Degroot ANJA, Van Dongen PWJ, Van Roosmalen J. Ergotamine-induced fetal distress: review of side-effects of ergot alkaloids during pregnancy. Eur J Obstet Gynecol Reprod Biol 1993; 51: 73-7
61. Graham JM, Marin-Padilla M, Hofnagel D. Jejunal atresia associated with Cafergot® ingestion during pregnancy. Clin Pediatr 1983; 22: 226-8
62. Hughes HE, Goldstein DA. Birth defects following maternal exposure to ergotamine, beta blockers and caffeine. J Med Genet 1988; 25: 396-9
63. Graf WD, Shepard TH. Uterine contraction in the development of Mobius syndrome. J Child Neurol 1997; 12: 225-7
64. Werler MM, Sheehan JE, Mitchell AA. Maternal medication use and risk of gastroschisis and small intestinal atresia. Am J Epidemiol 2002; 155: 26-31
65. Orioli IM, Castilla EE. Epidemiological assessment of misoprostol teratogenicity. Br J Obstet Gynecol 2000; 107: 519-23
66. Sayfan J. Ergotamine-induced anorectal strictures: report of five cases. Dis Colon Rectum 2002; 45 (2): 271-2
67. Papalampros EL, Salakou SG, Felekouras ES, et al. Ischemic necrosis of gastric wall after long-term ergotamine pill abuse: case report and review of the literature. Dig Dis Sci 2001; 46: 981-4
68. Spierings ELH, Saxena PR. Pharmacology of arteriovenous anastomoses. Adv Neurol 1982; 33: 291-4
69. Spierings ELH, Saxena PR. Effect of isometheptene on the distribution and shunting of 15 micrometer microspheres throughout the cephalic circulation of the cat. Headache 1980; 20: 103-6
70. Diamond S. Treatment of migraine with isometheptene, acetaminophen and dichloralphenazone combination: a double-blind, crossover trial. Headache 1976; 15: 282-87
71. Freitag FG, Cady R, DiSerio F, et al. Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine. Headache 2001; 41: 391-98
72. Hardebo JE, Edvinsson L. Reduced sensitivity to alpha- and beta-adrenergic receptor agonists of intra- and extra-cranial vessels during pregnancy: relevance to migraine. Acta Neurol Scand Suppl 1977; 64: 204-5
73. Diamond S, Medina JL. Isometheptene-a non-ergot drug in the treatment of migraine. Headache 1975; 15:211-13
74. Dodick DW, Martin V. Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. Cephalalgia 2004; 24: 417-24
75. Schenker S, Yang Y, Perez A, et al. Sumatriptan (Imitrex®) transport by the human placenta. Proc Soc Exp Biol Med 1995; 210: 213-20
76. Loder E. Safety of sumatriptan in pregnancy: a review of the data so far. CNS Drugs 2003; 17 (1): 1-7
77. Fox AW, Chambers CD, Anderson PO, et al. Evidence-based assessment of pregnancy outcome after sumatriptan exposure. Headache 2002; 42: 8-15
78. Evans RW, Diamond ML. Is sumatriptan use safe during pregnancy? Headache 2000; 40: 856-7
79. O'Quinn S, Ephross SA, William V, et al. Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study. Arch Gynecol Obstet 1999; 263: 7-12
80. Olesen C, Steffensen FH, Sorensen HT, et al. Pregnancy outcome following prescription for sumatriptan. Headache 2000; 40: 20-4
81. Shuhaiber S, Pastuszak A, Schick B, et al. Pregnancy outcome following first trimester exposure to sumatriptan. Neurology 1998; 51: 581-3
82. Kallen B, Lygner PE. Delivery outcome in women who used drugs for migraine during pregnancy, with special reference to sumatriptan. Headache 2001; 41: 351-6
83. Reiff-Eldridge R, Heffner CR, Ephross SA, et al. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am J Obstet Gynecol 2000; 182: 159-63
84. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335: 1010-5
85. Putnam GP, O'Quinn S, Bolden-Watson CP, et al. Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study. Cephalalgia 1999; 19: 668-75
86. Dowson AJ. Migraine: assessment and management. Int J Clin Pract 2001; 55: 684-9
87. Spierings ELH. Migraine prevention and errors in living: Dr Graham's lessons for patients and physicians. Headache 2002; 42: 152-3
88. Melchart D, Linde K, Fischer P, et al. Acupuncture for recurrent headaches: a systematic review of randomized controlled trials. Cephalalgia 1999; 19: 779-86
89. van der Kuy PH, Lohman JJ. A quantification of the placebo response in migraine prophylaxis. Cephalalgia 2002; 22: 265-70
90. Whitmarsh TE, Coleston-Shields DM, Steiner TJ. Double-blind randomized placebo-controlled study of homeopathic prophylaxis of migraine. Cephalalgia 1997; 17: 600-4
91. Fox AW. Complementary medicines. In: Fletcher AJ, Edwards LD, Fox AW, et al, editors. Principles and practice of pharmaceutical medicine. London: John Wiley and Sons, 2002: 281-6
92. Pfaffenrath V, Diener HC, Fischer M, et al. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis: a double-blind, multicentre, randomized, placebo- controlled dose-response study. Cephalalgia 2002; 22: 523-32
93. Murphy JJ, Heptinstall S, Mitchell JR. Randomised, double- blind, placebo-controlled trial of feverfew in migraine prevention. Lancet 1988; II: 189-92
94. Johnson ES, Kadam NP, Hylands DM, et al. Efficacy of feverfew as prophylactic treatment of migraine. BMJ (Clin Res) 1985; 291: 569-73
95. Grossmann M, Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int J Clin Pharmacol Ther 2000; 38: 430-5
96. Fox AW, de Sousa EAJ. "Herbal remedies" and patient protection. Headache 2001; 41: 323-6
97. Shahin M, Smith BL, Prakash AS. Bracken carcinogens in the human diet. Mutat Res 1999; 443: 69-79
98. Tomlinson B, Chan TYK, Chan JCN, et al. Toxicity of complementary therapies: an Eastern perspective. J Clin Pharmacol 2000; 40: 451-6
99. Nortier JL, Muniz Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aris-tolochia Fangchi). N Engl J Med 2000; 342: 1686-92
100. Henderson L, Yue QY, Bergquist C, et al. St. John's Wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54: 349-56
101. Mitchinson MJ. Methysergide and retroperitoneal fibrosis [letter]. Lancet 1987; I: 870
102. Limmroth V, Michel MC. The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers. Br J Clin Pharmacol 2001; 52: 237-43
103. Bernus I, Roberts MS, Rasiah RL, et al. Statistical moments for placental transfer of solutes in man. J Pharm Pharmacol 1999; 51: 1381-9
104. Smith MT, Livingstone I, Eadie MJ, et al. Metabolism of propranolol in the human maternal-placental-foetal unit. Eur J Clin Pharmacol 1983; 24: 727-32
105. Featherstone HJ. Fetal demise in a migraine patient on propranolol. Headache 1983; 23: 213-4
106. Chow T, Galvin J, McGovern B. Antiarrhythmic therapy in pregnancy and lactation. Am J Cardiol 1998; 82: 581-621
107. Paran E, Holzberg G, Mazor M, et al. Beta-adrenergic blocking agents in the treatment of pregnancy-induced hypertension. Int J Clin Pharmacol Ther 1995; 33: 119-23
108. Kleinman CS. Prenatal diagnosis and management of intrauterine arrhythmia. Fetal Ther 1986; 1: 92-5
109. Wagenvoort AM, van Vugt JM, Sobotka M, et al. Topical timolol therapy in pregnancy: is it safe for the fetus? Teratology 1998; 58: 258-62
110. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablet in migraine prophylaxis. Neurology 2002; 58: 1652-9
111. Mathew NT. Antiepileptic drugs in migraine prevention. Headache 2001; 41 Suppl. 1: S18-S24
112. Silberstein SD. Divalproex sodium in headache: literature review and clinical guidelines. Headache 1996; 36: 547-55
113. Adelman JU, Adelman LC, Von Seggern R. Cost-effectiveness of antiepileptic drugs in migraine prophylaxis. Headache 2002; 42: 978-83
114. Scott WJ, Schreiner CM, Nau H, et al. Valproate-induced limb malformations in mice associated with reduction in cellular pH. Reprod Toxicol 1997; 11: 483-93
115. Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry 2002; 63 Suppl. 4: 42-55
116. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention. JAMA 2004; 291: 965-73
117. Palmieri C, Canger R. Teratogenic potential of the newer antiepileptic drugs: what is known and how should this influence prescribing? CNS Drugs 2002; 16: 755-64
118. Vahedi K, Taupin P, Djomby R, et al., for the DIAMIG Investi-gators. Efficacy and tolerability of acetazolamide in migraine prophylaxis: a randomized placebo-controlled trial. J Neurol 2002; 249: 206-11
119. Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979; 36: 695-99
120. Wisner KL, Gelenberg AJ, Leonard H, et al. Pharmacologic treatment of depression during pregnancy. JAMA 1999; 282: 1264-9
121. Misri S, Kostaras D, Kostaras X. The use of selective serotonin reuptake inhibitors during pregnancy and lactation: current knowledge. Can J Psychiatry 2000; 45: 285-7
122. Diener HC, Matias-Guiu J, Hartung E, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine reduced doses: a comparison with propranolol 160mg daily. Cephalalgia 2002; 22: 209-21
123. Spierings ELH. Calcium entry blockers in migraine: the state of the art. In: Hartmann A, Kushchinsky W, editors. Cerebral ischemia and calcium. Berlin & Heidelberg: Springer-Verlag, 1989: 391-97
124. Spierings ELH, Messinger HB. Flunarizine vs pizotifen in migraine prophylaxis: a review of comparative studies. Cephalalgia 1988; 8 Suppl. 8: 27-30
125. Pfaffentrath V, Rehm M. Migraine in pregnancy: what are the safest treatment options? Drug Saf 1998; 19: 383-8
126. Rayburn WF, Lavin JP. Drug prescribing for chronic medical disorders during pregnancy: an overview. Am J Obstet Gynecol 1986; 155: 565-9
127. Silberstein SD. Headaches and women: treatment of the pregnant and lactating migraineur. Headache 1993; 33: 533-40
128. Miles CB. Treatment of migraine during pregnancy and lactation. S D J Med 1995; 48: 373-7
129. Paulson GW. Headaches in women, including women who are pregnant. Am J Obstet Gynecol 1995; 173: 1734-41
130. Rathmell JP, Viscomi CM, Ashburn MA. Management of non-obstetric pain during pregnancy and lactation. Anesth Analg 1997; 87: 1074-87
131. Marcus DA. Pregnancy and chronic headache. Exp Opin Pharmacother 2002; 3: 389-98
132. Hainline B. Migraine and other headache conditions. Adv Neurol 2002; 90: 25-40
133. Aube M. Migraine in pregnancy. Neurology 1999; 53 Suppl. 1: S26-8
134. Fuller RW, Snoody HD. Inhibition of serotonin uptake and the toxic interaction between meperidine and monoamine oxidase inhibitors. Toxicol Appl Pharmacol 1975; 32: 129-34
135. Mathew NT, Reuveni U, Perez F. Transformed or evolutive migraine. Headache 1987; 27: 102-6